Mylan awaits further Advair CRL
Mylan will receive a second complete response letter (CRL) refusing US approval for the firm’s Wixela Inhub generic version of Advair Diskus (fluticasone/salmeterol), the firm has revealed. The US Food and Drug Administration (FDA) will communicate “minor deficiencies” identified in the company’s abbreviated new drug application (ANDA) in a CRL on 27 June, the ANDA’s target action date. No details on the nature of the CRL were revealed by Mylan or the FDA. “Because our ANDA has received a priority designation, our approval could be received prior to the standard 90-day time period following the date of our response to the CRL,” Mylan observed. Upon receipt of the CRL, Mylan said it would determine “what, if any, impact that it could have on our full-year 2018 outlook”.
You may also be interested in...
Mylan Gears Up To Launch US Advair Rival This Month
Mylan has revealed that its Wixela Inhub US rival to GSK’s Advair Diskus will be on the market by the end of February, acting quickly after their recent FDA approval.
Mylan’s Nod For US Advair Rival Puts It A Year Ahead Of The Pack
The FDA’s approval for Mylan’s Wixela Inhub generic rival to GSK’s Advair Diskus is likely to give the company around a year’s head-start on other US generics being developed by Sandoz and Hikma.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add a new product – Tibsovo, Servier’s treatment for IDH1-mutated acute myeloid leukemia and IDH1-mutated cholangiocarcinoma.